Literature DB >> 9360850

Influence of fibrinogen on cardiovascular disease.

W B Kannel1.   

Abstract

Results from prevalence, case-control, angiographic and echocardiographic investigations incriminate elevated fibrinogen levels as a strong independent risk factor for the occurrence of initial and recurrent cardiovascular events. Average fibrinogen levels are higher in women and persons with other risk factors including hypertension, diabetes, cigarette smoking, obesity, elevated haematocrit value and dyslipidaemia. Fibrinogen tends to cluster with most of these major atherogenic cardiovascular risk factors and further enhances their risk. Prospective data indicate a relationship between fibrinogen and the subsequent development of all the major atherosclerotic cardiovascular events including coronary heart disease, stroke and peripheral artery disease. Fibrinogen adds to the multivariate risk of cardiovascular events, especially in the high risk subset of the population. In the Framingham Heart Study, a comparison of risk gradients, exemplified by their regression coefficients, was similar for all outcomes (coronary heart disease, stroke, peripheral artery disease and cardiovascular disease) in men, whereas, in women, the risk gradient for fibrinogen appeared weakest for stroke. Fibrinogen exerts an independent influence on the frequency of cardiovascular disease in general, and coronary heart disease in particular. For example, in both men and women, each standard deviation increase in fibrinogen level (about 0.56 g/L) within the range of usual values is associated with about a 20% age- and risk factor-adjusted increase in the incidence of an initial cardiovascular event. Fibrinogen should be added to the list of major atherogenic cardiovascular risk factors; in addition, there is a need for intervention trials designed to test the efficacy of lowering fibrinogen in individuals at high risk for cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360850     DOI: 10.2165/00003495-199700543-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  27 in total

1.  Plasma fibrinogen and ischemic heart disease risk factors.

Authors:  L Møller; T S Kristensen
Journal:  Arterioscler Thromb       Date:  1991 Mar-Apr

Review 2.  27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management.

Authors:  R M Califf; P W Armstrong; J R Carver; R B D'Agostino; W E Strauss
Journal:  J Am Coll Cardiol       Date:  1996-04       Impact factor: 24.094

3.  Influence of smoking and plasma factors on patency of femoropopliteal vein grafts.

Authors:  S Wiseman; G Kenchington; R Dain; C E Marshall; C N McCollum; R M Greenhalgh; J T Powell
Journal:  BMJ       Date:  1989-09-09

4.  Clinical, haemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication.

Authors:  J A Dormandy; E Hoare; J Colley; D E Arrowsmith; T L Dormandy
Journal:  Br Med J       Date:  1973-12-08

5.  Relation of fibrinogen to presence and severity of coronary artery disease is independent of other coexisting heart disease. The ECAT Angina Pectoris Study Group.

Authors:  I Bolibar; J Kienast; S G Thompson; R Matthias; H Niessner; C Fechtrup
Journal:  Am Heart J       Date:  1993-06       Impact factor: 4.749

6.  Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature.

Authors:  E Ernst; K L Resch
Journal:  Ann Intern Med       Date:  1993-06-15       Impact factor: 25.391

7.  Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men.

Authors:  J Heinrich; L Balleisen; H Schulte; G Assmann; J van de Loo
Journal:  Arterioscler Thromb       Date:  1994-01

8.  Fibrinogen as a risk factor for stroke and myocardial infarction.

Authors:  L Wilhelmsen; K Svärdsudd; K Korsan-Bengtsen; B Larsson; L Welin; G Tibblin
Journal:  N Engl J Med       Date:  1984-08-23       Impact factor: 91.245

9.  Plasma fibrinogen levels as an independent indicator of severity of coronary atherosclerosis.

Authors:  K Handa; S Kono; K Saku; J Sasaki; T Kawano; Y Sasaki; T Hiroki; K Arakawa
Journal:  Atherosclerosis       Date:  1989-06       Impact factor: 5.162

10.  Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study.

Authors:  G D Lowe; F G Fowkes; J Dawes; P T Donnan; S E Lennie; E Housley
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690

View more
  13 in total

1.  [Randomised clinical trial of an intensive intervention into life-styles of patients with hyperfibrinogenaemia in primary prevention of cardiovascular pathology in primary health care].

Authors:  J J Rodríguez Cristóbal; F Benavides Márquez; C Villaverde Grote; E Peña Sendra; F Flor Serra; P Travé Mercadé
Journal:  Aten Primaria       Date:  2005-03-31       Impact factor: 1.137

Review 2.  Management of the hypertensive patient who smokes.

Authors:  H Pardell; R Tresserras; E Saltó; P Armario; R Hernández
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

3.  A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo.

Authors:  Christopher P Cannon; Cong Chen; Sean P Curtis; John Viscusi; Tuli Ahmed; Peter M Dibattiste
Journal:  Arch Drug Inf       Date:  2008-07

4.  Fibrinogen and rhegmatogenous retinal detachment: a pilot prospective study.

Authors:  Ip Theocharis
Journal:  Clin Ophthalmol       Date:  2010-02-18

5.  4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome.

Authors:  Muammer Karadeniz; Mehmet Erdogan; Afig Berdeli; Fusun Saygili; Candeger Yilmaz
Journal:  J Assist Reprod Genet       Date:  2007-07-28       Impact factor: 3.412

6.  Migraine and vascular disease biomarkers: A population-based case-control study.

Authors:  Gretchen E Tietjen; Jagdish Khubchandani; Nabeel Herial; Inge H Palm-Meinders; Hille Koppen; Gisela M Terwindt; Mark A van Buchem; Lenore J Launer; Michel D Ferrari; Mark C Kruit
Journal:  Cephalalgia       Date:  2017-03-15       Impact factor: 6.292

Review 7.  Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.

Authors:  William B Kannel
Journal:  Lipids       Date:  2005-12       Impact factor: 1.880

8.  Randomised clinical trial of an intensive intervention in the primary care setting of patients with high plasma fibrinogen in the primary prevention of cardiovascular disease.

Authors:  Juan José Rodríguez Cristóbal; Carlos Alonso-Villaverde Grote; Pere Travé Mercadé; José Ma Pérez Santos; Esther Peña Sendra; Anna Muñoz Lloret; Cristina Fernández Pérez; Domingo Bleda Fernández
Journal:  BMC Res Notes       Date:  2012-03-01

9.  Relationship of opium dependency and stroke.

Authors:  Akbar Hamzei Moqaddam; Seyyed Mohammad Reza Ahmadi Musavi; Khatereh Khademizadeh
Journal:  Addict Health       Date:  2009

10.  Comparison between Homocysteine, Fibrinogen, PT, PTT, INR and CRP in Male Smokers with/without Addiction to Opium.

Authors:  Nahid Azdaki; Mahmood Zardast; Gholamreza Anani-Sarab; Hamid Abdorrazaghnaejad; Mohammad Reza Ghasemian; Amin Saburi
Journal:  Addict Health       Date:  2017-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.